Health Catalyst, Inc. HCAT
Computer Software: Programming Data Processing · IPO 2019 · data as of November 13, 2026
Health Catalyst, Inc. (HCAT) is a technology company listed in the US with a market value of about $115M. In the twelve months to September 30, 2026 it had revenue of $272M and net income of -$202M, a net margin of -74.2%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is shareholder returns (0/5).
Key numbers: a price to free cash flow of 4.5, 5-year revenue growth of 10% a year, a 5-year average ROIC of -17%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 46% below the current price.
About Health Catalyst
Health Catalyst is listed in the US and classified in computer software: programming data processing, IPO year 2019. Revenue went from $73M in 2017 to $311M in 2025, growth of about 19.9% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 29% over three years (dilution for shareholders). It spends 16% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- P/FCF below 20
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $272M | $311M | $307M | $296M | $276M | $242M | $189M | $155M | $113M | $73M |
| Net income | -$202M | -$178M | -$70M | -$118M | -$137M | -$153M | -$115M | -$60M | -$62M | -$47M |
| Free cash flow | $26M | -$237000 | $13M | -$34M | -$37M | -$34M | -$34M | -$34M | -$42M | -$39M |
| EPS (diluted) | $-2.85 | $-2.55 | $-1.15 | $-2.09 | $-2.63 | $-3.23 | $-2.91 | $-12.86 | $-23.76 | $-12.13 |
| Net margin | -74.2% | -57.2% | -22.7% | -39.9% | -49.7% | -63.3% | -60.9% | -38.8% | -55.1% | -64.4% |
| ROIC | — | -30.5% | -7.2% | -16.3% | -16.4% | -15.6% | -16.1% | -17.1% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Health Catalyst stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 46% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Health Catalyst pay a dividend?
Not currently.
Is Health Catalyst a good stock to buy?
We do not give buy or sell advice. Health Catalyst scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.